Key result
Osteosarcoma survivors had significantly elevated mean hsCRP (3.0 vs 1.6 mg/L) and VCAM-1 (86.4% vs 42.1%) compared to controls, indicating vascular inflammation and early atherogenesis.
Why the study?
Do osteosarcoma survivors have evidence of vascular inflammation and dyslipidemia compared to healthy controls?
Observational (n=24)
No
Do osteosarcoma survivors have evidence of vascular inflammation and dyslipidemia compared to healthy controls?
Osteosarcoma survivors demonstrate evidence of vascular inflammation, dyslipidemia, and early atherogenesis a median of 14 years after diagnosis.
May warrant CV risk monitoring in osteosarcoma survivors; leaves open prospective links to clinical events.
BACKGROUND: Cardiovascular-related toxicities have been reported among survivors of osteosarcoma. METHODS: Fasting blood samples from 24 osteosarcoma survivors were analyzed for high-sensitivity C-reactive protein (hsCRP), triglycerides, total cholesterol, high-density lipoprotein (HDL), apolipoprotein-ß, lipoprotein (a), fibrinogen, circulating endothelial cells (CECs), and surface expression of vascular cell adhesion molecule-1 (VCAM-1). Values were compared to subjects in the natural history Coronary Artery Risk Development in Young Adults (CARDIA) cohort study except for CECs and VCAM-1 expression, which were compared to controls studied at the University of Minnesota Lillehei clinical trials unit. PROCEDURE: Survivors (54.2% male), median age 18 years (9-32) at diagnosis, 36.5 years (20-56) at evaluation were treated with a variety of chemotherapeutic exposures, all but one were exposed to doxorubicin (median dose 450 mg/m(2) ; range: 90-645 mg/m(2)), 14 (58.3%) received cisplatin, and 3 (12.5%) were exposed to carboplatin. Two survivors (8.3%) received radiation therapy for disease relapse. Compared to CARDIA subjects, mean hsCRP (3.0 mg/L ± 2.0 vs. 1.6 ± 2.3), triglycerides (151 mg/dl ± 81.7 vs. 95.4 ± 101.3), lipoprotein (a) (34.9 mg/dl ± 17.7 vs. 13.8 ± 22.0), and fibrinogen (315.0 mg/dl ± 49.3 vs. 252.4 ± 61.7) were significantly elevated. The number of CECs (0.47 cells/ml ± 2.5 vs. 0.92 ± 2.5) did not differ while surface expression of VCAM-1 (86.4% ± 34.0 vs. 42.1 ± 33.8) was significantly elevated compared to controls. CONCLUSIONS: Among survivors of osteosarcoma, assessed a median of 14 years from diagnosis, there is evidence of vascular inflammation, dyslipidemia, and early atherogenesis.
No takes yet. Share an insight, caveat, or question.
Mulrooney et al. (2013) conducted an observational in Osteosarcoma survivors (n=24). Prior treatment for osteosarcoma vs. Healthy controls (CARDIA cohort and University of Minnesota controls) was evaluated on High-sensitivity C-reactive protein (hsCRP) (mg/L). Osteosarcoma survivors had significantly elevated mean hsCRP (3.0 vs 1.6 mg/L) and VCAM-1 (86.4% vs 42.1%) compared to controls, indicating vascular inflammation and early atherogenesis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: